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Background: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the
gastrointestinal tract. Extragastrointestinal stromal tumors (eGISTs) of the mesoileum are extremely rare and are
usually treated with surgery combined with imatinib therapy.
Case presentation: We present the case of a 43-year-old man who developed a large eGIST in the mesoileum.
Abdominal/pelvic computed tomography revealed a large heterogeneous mass with cystic and solid components
that measured 20.0 × 12.0 × 8.0 cm. Three cycles of neoadjuvant chemotherapy with epirubicin, cyclophosphamide
and hydroxycamptothecin; en bloc resection; and three more cycles of adjuvant chemotherapy with the same
regimen and drugs resulted in five years of disease-free survival without any symptoms.
Conclusions: Although imatinib treatment is usually chosen for eGISTs, resistance to imatinib remains a concern;
these patients may receive neoadjuvant or adjuvant chemotherapy. In case of the former, further treatment, that is,
surgery or adjuvant chemotherapy, depends on tumor response to the neoadjuvant chemotherapy. In addition, this
treatment for eGIST is not only beneficial but also economical for patients compared with imatinib. A novel
treatment approach that combined neoadjuvant chemotherapy, surgery and adjuvant chemotherapy resulted in
long-term survival in our patient, thus showing promise as a potential therapy for eGISTs.
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Although gastrointestinal stromal tumors (GISTs) are rare,
they are the most common mesenchymal tumor of the
gastrointestinal (GI) tract. However, there are a few clinical
reports of extragastrointestinal stromal tumors (eGISTs)
sharing the morphological, immunological, molecular and
genetic traits of GISTs and originating in areas external to
the GI tube [1,2], such as the mesentery, omentum, vagina,
inguinal hernia sac, rectovaginal septum, ovary, pleura,
scrotum, seminal vesicles and abdominal wall [3-10]. To
the best of our knowledge, cases of eGISTs originating in
the mesoileum have been rarely reported. Initial reports* Correspondence: weiqiang933@126.com
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reproduction in any medium, provided the orhave shown the ineffectiveness of conventional chemother-
apy and radiotherapy for GISTs (<10% response) [1],
although some reports have shown moderate effectiveness
of en bloc resection with adjuvant imatinib therapy for
eGISTs [11-13]. However, further evidence from a larger
number of cases is required to clarify the effectiveness of
this treatment regime. Other reports have demonstrated
the development of resistance to imatinib in patients
with metastases or recurrent GISTs that were then
left untreated, thus increasing the risk of death
[14,15]. Here we present a case of eGIST that showed
an unexpected but interesting response to a novel treat-
ment approach that combined neoadjuvant chemotherapy,
surgery and adjuvant chemotherapy in a 43-year-old man.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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A 43-year-old man was referred to our institute after com-
puted tomography (CT) performed for lower abdominal
pain and postprandial fullness at a local hospital revealed
a heterogeneous mass comprising mixed cystic and solid
components and measuring 20.0 × 12.0 × 8.0 cm. Lymph
node involvement or metastasis was not detected.
Abdominal ultrasound confirmed the findings by re-
vealing a heterogeneous mass in the same location.
The patient gave no history of bowel habit changes,
fever, chills, nausea, trauma, past surgeries or family
history of malignancy.
Physical examination revealed slight abdominal distension
and tenderness. Palpation revealed a large, nonpulsatile,
fixed, moderately tender abdominal mass. The results of
tests for examining blood, stool and serum tumor markers
(CA-19-9, CA-125 and CEA) were unremarkable, as were
chest X-ray and rectal examination findings.
Laparotomy revealed a large, brownish mass adherent to
the colon, bladder and abdominal wall. These findings in
addition to difficult hemostasis prevented resection of the
mass. A biopsy sample obtained during the laparotomy
procedure revealed inflammatory granulomas and necrosis.
Fine needle aspiration cytology suggested the tumor to be
a sarcoma with indeterminate subclassification. On the
basis of the above findings, the patient was administered
three cycles (every 28 days) of intravenous neoadjuvant
chemotherapy with 40 mg/m2 epirubicin, 500 mg/m2
cyclophosphamide and 15 mg hydroxycamptothecin in a
day. Subsequent CT revealed the mass to have diminished
in size, now measuring 6.5 × 5.0 × 5.0 cm (Figure 1). This
enabled en bloc resection of the mass. The gross specimenFigure 1 CT Imaging after three cycles of neoadjuvant chemotherapywas a lobulated, grayish-white soft tissue mass measuring
6.5 × 5.0 × 4.5 cm. Histopathological examination revealed
atypical spindle cells in a whorled and paliform array. The
average mitotic count was 3 mitoses per 50 high power
fields (HPFs). Immunohistochemical staining was diffusely
and strongly positive for CD117, CD34 and Ki-67 (>10%)
(Figure 2); weakly positive for S-100; and negative for
desmin and smooth muscle actin (SMA). Three cycles
of chemotherapy identical to those administered as
neoadjuvant chemotherapy were administered after
surgery. The patient exhibited five-year disease-free
survival without any symptoms (Figure 3).
Discussion
GISTs originate from the interstitial cells of Cajal or their
stem cell precursors and account for approximately 5% of
GI tract malignancies [1]. However, a few reports have
documented eGISTs with properties similar to those of
GISTs and arising from multiple extragastrointestinal sites
[1-10]. Despite the presence of two controversial hypoth-
eses concerning the origin of eGISTs, the diagnostic tests,
immunohistochemical staining and large tumor size sug-
gested a primary malignant eGIST of the mesoileum, an
extremely rare entity. A majority of GISTs are comprised of
a uniform cell type, either spindle-shaped, epitheloid or
mixed cell type [16]. Positive immunohistochemical stain-
ing for CD117 is a defining feature of GISTs [17] and CD34
has been proposed as a reproducible marker [1,14]. Some
reports, however, showed platelet-derived growth factor
receptor-α (PDGFRA) gene mutations in eGISTs negative
for CD117, also showed a strong correlation between an
increased Ki-67 labeling index and a poor prognosis. CT, computed tomography.
Figure 2 Immunohistochemical feature of tumor. A standard H & E assay of tumor cells is observed in (A), tumor cells characteristically
express CD117 (B), CD34 (C), and ki67 (D).
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revealed a tumor comprising atypical spindle cells in
a whorled paliform array. Immunohistochemical staining
revealed diffuse and strong positivity for CD117, CD34
and Ki-67. According to the findings at the first sur-
gery, as well as pathological findings, the patient wasFigure 3 CT Imaging in follow-up within fifth year. CT, computed tomoat a high risk of recurrence despite the lower rate of
karyokinesis.
The current therapy for GISTs and eGISTs is en
bloc resection with adjuvant imatinib mesylate therapy.
Extensive lymphadenectomy is not recommended because
of the low incidence (<10%) of lymph node metastases.graphy.
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two years, even after en bloc resection [20]. Increased
cellularity, mitotic rate (>5/50 HPFs) and Ki-67 labeling
index (>10%), necrosis, cyst formation and tumor size are
parameters for evaluating GISTs, of which the first three
are predictors of poor prognosis [21,22]. A mitotic rate
of >2/50 HPFs, increased cellularity, and necrosis, and
cyst formation have also been found to indicate aggressive
behavior [23]. In our case, an increased mitotic rate
(>3/50 HPF) and Ki-67 labeling index (>10%), necrosis,
cyst formation and tumor size (>5 cm) all conferred a
higher risk for recurrence and a worse prognosis. Initial
reports indicated that conventional chemotherapy
and radiotherapy were ineffective against GISTs
(<10% response) [1]. Some reports showed success in
cases in which the tumor was managed with en bloc
resection combined with adjuvant imatinib therapy.
However, resistance to imatinib has been reported in
patients with metastases or recurrences [11-13]. A
few reports have demonstrated the efficacy of sunitinib in
patients resistant to imatinib [11-13], but further studies
are needed for confirmation. No method has been very
effective in patients resistant to imatinib [14,15]. Therapy
for eGISTs is similar to that of GISTs. Our patient was
initially diagnosed with sarcoma and was administered three
cycles of neoadjuvant chemotherapy used for sarcoma,
resulting in a positive chemical response. Following en bloc
resection, three more cycles of the same chemotherapy
were administered (considering first therapeutic efficacy
and economic benefits). Under close follow-up, the patient
remains free of disease at five years. The possible mecha-
nisms could be considered as follows: 1) antibiotics admin-
istered after the first surgery relieved inflammation and
decreased tumor volume, probably increased the patient’s
appetite and immunological capability of resistance to the
tumor according to the first postoperative results; some
reports also showed that the antibiotics indirectly exert their
beneficial effects by immunomodulation [24]; and 2) the
cytotoxic chemotherapy effect on different cell cycles
inhibited the formation of tumorous DNA and RNA and
killed tumor cells. Yet, the molecular mechanisms respon-
sible for the effects of eGISTs cell functions remain unclear.
Conclusions
There are too few data on eGISTs to make a final con-
clusion regarding treatment, prognosis and recurrence.
Although imatinib treatment is usually chosen for
eGISTs, resistance to imatinib remains a concern; these
patients may receive neoadjuvant or adjuvant chemo-
therapy. In the case of the former, further treatment
(that is, surgery or other treatments) depends on tumor
response to the initial chemotherapy. In addition, this
treatment for eGIST is not only beneficial but also eco-
nomical for patients compared with imatinib. A noveltreatment approach that combined neoadjuvant chemo-
therapy, surgery and adjuvant chemotherapy resulted in
long-term survival in our patient, thus showing promise
as a potential therapy for eGISTs.
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